{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:35:57Z","timestamp":1787016957092,"version":"build-2736575974"},"reference-count":241,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T00:00:00Z","timestamp":1608681600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2020,9,10]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups. The rapid introduction of immunotherapeutic agents into the clinic, however, has presented significant questions regarding optimal treatment scheduling around existing chemotherapy\/radiation options, as well as a need for improved understanding of how to properly manage patients and recognize toxicities. To address these challenges, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in lymphoma to develop a clinical practice guideline for the education of healthcare professionals on various aspects of immunotherapeutic treatment. The panel discussed subjects including treatment scheduling, immune-related adverse events (irAEs), and the integration of immunotherapy and stem cell transplant to form recommendations to guide healthcare professionals treating patients with lymphoma.<\/jats:p>","DOI":"10.1136\/jitc-2020-001235","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T11:22:46Z","timestamp":1608808966000},"page":"e001235","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01712490","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01100502","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00848926","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02181738","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01592370","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02572167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02453594","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03138499","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03907488","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02684292","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00140582","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00003150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00064116","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00001337","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01880567","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00722137","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00921414","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01059630","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01332968","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01287741","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00185393","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00866047","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01777152","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01578499","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01421667","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02257567","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01728805","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02576990","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00737529","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01938001","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01996865","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01476787","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01650701","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01197560","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02348216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02445248","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02601313","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02399085","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04182204","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03274492","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03570892","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02631044","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03575351","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03105336","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03391466","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03366272","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02285062","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02763319","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02367040","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02626455","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02793583","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00281918","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00090051","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02048813","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01010061","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00748189","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00802737","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00824265","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00349349","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00349349","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00046683","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03624036","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03331198","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02950051","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02301156","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02612311","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03094286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02408861","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01712490","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01100502","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00848926","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02181738","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01592370","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02572167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02453594","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00140582","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00003150","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00064116","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03397706","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01880567","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01059630","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01332968","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01287741","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00185393","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00866047","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01777152","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01578499","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02257567","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01728805","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02576990","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00737529","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01938001","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01996865","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01476787","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01650701","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02348216","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02601313","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02399085","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00281918","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00090051","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02048813","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01010061","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00748189","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00802737","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00824265","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00349349","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00046683","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03892044","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03514017","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sattva S","family":"Neelapu","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Adkins","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M","family":"Ansell","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Mayo Clinic Cancer Center, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Brody","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2075-434X","authenticated-orcid":false,"given":"Mitchell S","family":"Cairo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology, New York Medical College At Maria Fareri Children\u2019s Hospital, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hematology-Oncology Division, Wilmot Cancer Institute University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin P","family":"Kline","sequence":"additional","affiliation":[{"name":"Department of Medicine Section of Hematology\/Oncology, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Levy","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L","family":"Porter","sequence":"additional","affiliation":[{"name":"Cell Therapy and Transplant and Division of Hematology Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Weill Cornell Medical College, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Werner","sequence":"additional","affiliation":[{"name":"Founder and CEO of HomeX, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Bishop","sequence":"additional","affiliation":[{"name":"Department of Medicine Section of Hematology\/Oncology, University of Chicago, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,24]]},"reference":[{"key":"2025100303332068000_8.2.e001235.1","unstructured":"Leukemia & Lymphoma Society . Facts and statistics, 2019. Available: http:\/\/www.lls.org\/facts-and-statistics\/facts-and-statistics-overview"},{"key":"2025100303332068000_8.2.e001235.2","unstructured":"American Cancer Society . Cancer statistics center, 2019. Available: https:\/\/cancerstatisticscenter.cancer.org\/"},{"key":"2025100303332068000_8.2.e001235.3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0188-z"},{"key":"2025100303332068000_8.2.e001235.4","unstructured":"The Society for Immunotherapy of Cancer . SITC cancer immunotherapy guidelines. Available: https:\/\/www.sitcancer.org\/research\/cancer-immunotherapy-guidelines"},{"key":"2025100303332068000_8.2.e001235.5","unstructured":"Institute of Medicine , Graham R , Mancher M , Wolman DM , et al , eds. Clinical practice guidelines we can trust. Washington, DC: The National Academies Press, 2011: 290."},{"key":"2025100303332068000_8.2.e001235.6","doi-asserted-by":"crossref","unstructured":"Vist GE , Bryant D , Somerville L , et al . Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database of Systematic Reviews 2008;60.doi:10.1002\/14651858.MR000009.pub4","DOI":"10.1002\/14651858.MR000009.pub3"},{"key":"2025100303332068000_8.2.e001235.7","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.55.6.368"},{"key":"2025100303332068000_8.2.e001235.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.016"},{"key":"2025100303332068000_8.2.e001235.9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-101899"},{"key":"2025100303332068000_8.2.e001235.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011"},{"key":"2025100303332068000_8.2.e001235.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2711-1"},{"key":"2025100303332068000_8.2.e001235.12","unstructured":"National Comprehensive Cancer Network . B-Cell lymphomas, 2018. Available: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf"},{"key":"2025100303332068000_8.2.e001235.13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.15386\/cjmed-339","article-title":"Chemotherapy-Induced cardiotoxicity: pathophysiology and prevention","volume":"87","author":"Csapo","year":"2014","journal-title":"Med Pharm Rep"},{"key":"2025100303332068000_8.2.e001235.14","doi-asserted-by":"crossref","first-page":"317659","DOI":"10.4061\/2011\/317659","article-title":"Radiation-Induced heart disease: a clinical update","volume":"2011","author":"Yusuf","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"2025100303332068000_8.2.e001235.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9"},{"key":"2025100303332068000_8.2.e001235.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102"},{"key":"2025100303332068000_8.2.e001235.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200205023461821"},{"key":"2025100303332068000_8.2.e001235.18","unstructured":"Millennium Pharmaceuticals, Inc, Seattle Genetics, Inc, Takeda . A frontline therapy trial in participants with advanced classical Hodgkin lymphoma 2017 [updated April 20], 2017. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01712490"},{"key":"2025100303332068000_8.2.e001235.19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for Stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2025100303332068000_8.2.e001235.20","unstructured":"Seattle Genetics, Inc . ADCETRIS prescribing information Bothell, WA. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125388"},{"key":"2025100303332068000_8.2.e001235.21","unstructured":"Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc . A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at high risk of residual Hodgkin lymphoma following stem cell transplant (The AETHERA Trial) 2014 [updated August 31]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01100502"},{"key":"2025100303332068000_8.2.e001235.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117429"},{"key":"2025100303332068000_8.2.e001235.23","unstructured":"Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc . A pivotal open-label trial of brentuximab vedotin for Hodgkin lymphoma 2010 [updated August]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00848926"},{"key":"2025100303332068000_8.2.e001235.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595801"},{"key":"2025100303332068000_8.2.e001235.25","unstructured":"Squibb B-M . Study of Nivolumab in Patients With Classical Hodgkin\u2019s Lymphoma (Registrational) 2017 [updated August 31]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT02181738"},{"key":"2025100303332068000_8.2.e001235.26","unstructured":"Squibb B-M , Janssen LP . An investigational immuno-therapy study to determine the safety and effectiveness of nivolumab and daratumumab in patients with multiple mye loma 2022 [updated January 13]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01592370"},{"key":"2025100303332068000_8.2.e001235.27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"2025100303332068000_8.2.e001235.28","unstructured":"Squibb B-M . OPDIVO prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125554"},{"key":"2025100303332068000_8.2.e001235.29","unstructured":"Seattle Genetics, Inc. Squibb B-M . A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma 2018 [updated March 1]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT02572167"},{"key":"2025100303332068000_8.2.e001235.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"2025100303332068000_8.2.e001235.31","unstructured":"Merck Sharp & Dohme Corp . Study of pembrolizumab (MK-3475) in participants with relapsed or refractory class ical Hodgkin Lymphoma (MK-3475-087\/KEYNOTE-087) 2021 [updated April 20] Merck Sharp & Dohme Corp. Available: https:\/\/ClinicalTrials.gov\/show\/NCT02453594"},{"key":"2025100303332068000_8.2.e001235.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"2025100303332068000_8.2.e001235.33","unstructured":"Merck & Co. Inc . Pembrolizumab (KEYTRUDA) prescribing information, 2017. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125514"},{"key":"2025100303332068000_8.2.e001235.34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"2025100303332068000_8.2.e001235.35","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008389119525"},{"key":"2025100303332068000_8.2.e001235.36","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\"s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.37","unstructured":"Genentech . RITUXAN prescribing information South San Francisco, CA. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=103705"},{"key":"2025100303332068000_8.2.e001235.38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"2025100303332068000_8.2.e001235.39","unstructured":"Lymphoma Study Association, HOVON Dutch Haemato-Oncology Association, German Low Grade Lymphoma Study Group . Primary rituximab and maintenance 2007 [updated May]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00140582"},{"key":"2025100303332068000_8.2.e001235.40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"The Lancet"},{"key":"2025100303332068000_8.2.e001235.41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.1561"},{"key":"2025100303332068000_8.2.e001235.42","unstructured":"Eastern Cooperative Oncology Group, National Cancer Institute, Cancer and Leukemia Group B . Combination chemotherapy with or without monoclonal antibody therapy in treating older patients with non-hodgkin\u2019s lymphoma. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00003150"},{"key":"2025100303332068000_8.2.e001235.43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100303332068000_8.2.e001235.44","unstructured":"NCIC Clinical Trials Group, Canadian Cancer Trials Group . Combination chemotherapy with or without rituximab in treating patients with non-hodgkin\u2019s lymphoma 2010 [updated December]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00064116"},{"key":"2025100303332068000_8.2.e001235.45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"2025100303332068000_8.2.e001235.46","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"2025100303332068000_8.2.e001235.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"2025100303332068000_8.2.e001235.48","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14951"},{"key":"2025100303332068000_8.2.e001235.49","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood.V92.9.3137","article-title":"Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome","volume":"92","author":"Benkerrou","year":"1998","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.50","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200104270-00012"},{"key":"2025100303332068000_8.2.e001235.51","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2000.18.21.3622","article-title":"Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center","volume":"18","author":"Mamzer-Bruneel","year":"2000","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.52","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1182\/blood.V86.9.3333.bloodjournal8693333","article-title":"Aggressive treatment for postcardiac transplant lymphoproliferation","volume":"86","author":"Swinnen","year":"1995","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-024703"},{"key":"2025100303332068000_8.2.e001235.54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10595"},{"key":"2025100303332068000_8.2.e001235.55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06228.x"},{"key":"2025100303332068000_8.2.e001235.56","unstructured":"Viracta Therapeutics, Inc . Dose escalation & expansion study of oral VRx-3996 & Valganciclovir in subjects with EBV-Associated lymphoid malignancies 2020 [updated January]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT03397706"},{"key":"2025100303332068000_8.2.e001235.57","unstructured":"M. D. Anderson Cancer Center, National Cancer Institute . Ibrutinib and rituximab in treating patients with relapsed or refractory mantle cell lymphoma or older patients with newly diagnosed mantle cell lymphoma 2020 [updated July 31]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01880567"},{"key":"2025100303332068000_8.2.e001235.58","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"2025100303332068000_8.2.e001235.59","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348367"},{"key":"2025100303332068000_8.2.e001235.60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"2025100303332068000_8.2.e001235.61","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"2025100303332068000_8.2.e001235.62","unstructured":"Celltrion, Inc . TRUXIMA prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761088"},{"key":"2025100303332068000_8.2.e001235.63","unstructured":"Pfizer, Inc . RUXIENCE prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761103"},{"key":"2025100303332068000_8.2.e001235.64","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1200\/JCO.19.02953","article-title":"Understanding the role of comparative clinical studies in the development of oncology biosimilars","volume":"38","author":"Stebbing","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.65","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40259-019-00395-w","article-title":"Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price!","volume":"34","author":"Dutta","year":"2020","journal-title":"BioDrugs"},{"key":"2025100303332068000_8.2.e001235.66","unstructured":"Genentech . RITUXAN HYCELA prescribing information South San Francisco. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761064"},{"key":"2025100303332068000_8.2.e001235.67","unstructured":"Genentech, Inc Roche Pharma AG . A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin\u2019s Lymphoma (GADOLIN) 2014 [updated September 30]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01059630"},{"key":"2025100303332068000_8.2.e001235.68","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.5070"},{"key":"2025100303332068000_8.2.e001235.69","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30097-3"},{"key":"2025100303332068000_8.2.e001235.70","unstructured":"Genentech . GAZYVA prescribing information South San Francisco, CA. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125486"},{"key":"2025100303332068000_8.2.e001235.71","unstructured":"Hoffmann-La Roche, German Low Grade Lymphoma Study Group, Institute of Cancer Research, United Kingdom . A study of obinutuzumab (RO5072759) plus chemotherapy in comparison with rituximab plus chemotherapy followed by obinutuzumab or rituximab maintenance in patients with untreated advanced indolent non-hodgkin\u2019s lymphoma (GALLIUM) 2016 [updated February 1]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01332968"},{"key":"2025100303332068000_8.2.e001235.72","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100303332068000_8.2.e001235.73","unstructured":"Fondazione Italiana Linfomi ONLUS. La-Roche H . A study of Obinutuzumab in combination with CHOP chemotherapy versus rituximab with CHOP in participants with CD20-positive diffuse large B-cell lymphoma (GOYA). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01287741"},{"key":"2025100303332068000_8.2.e001235.74","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.75","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-002-0027-y"},{"key":"2025100303332068000_8.2.e001235.76","unstructured":"Witzig T , Gordon L , Wiseman G , eds. Reduced dose Zevalin is safe and effective in patients with relapsed or refractory, low grade, follicular or CD20 (+) transformed B cell non-Hodgkin\u2019s lymphoma (L\/F\/T NHL) and mild thrombocytopenia. Blood. WASHINGTON, DC 20036 USA: AMER SOC HEMATOLOGY 1900 MSTREET. NW SUITE 200, 2000."},{"key":"2025100303332068000_8.2.e001235.77","unstructured":"Witzig T , White C , Gordon L . Response to Zevalin is superior to response to rituximab regardless of age and extent of disease. Proc Am Soc Clin Oncol 2001."},{"key":"2025100303332068000_8.2.e001235.78","article-title":"Zevalin radioimmunotherapy of rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"96","author":"Witzig","year":"2000","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.79","unstructured":"Spectrum Pharms . ZEVALIN prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125019"},{"key":"2025100303332068000_8.2.e001235.80","unstructured":"Bayer . Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy, 2008. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00185393"},{"key":"2025100303332068000_8.2.e001235.81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2015"},{"key":"2025100303332068000_8.2.e001235.82","first-page":"63226","article-title":"Glaxosmithkline LLC; withdrawal of approval of the indication for treatment of patients with relapsed or refractory, low grade, follicular, or transformed CD20 positive non-Hodgkin\"s lymphoma who have not received prior rituximab; BEXXAR","volume":"78","author":"GlaxoSmithKline","year":"2013","journal-title":"Federal Register"},{"key":"2025100303332068000_8.2.e001235.83","unstructured":"Seattle Genetics Inc, Millennium Pharmaceuticals Inc . A phase 2 open label trial of Brentuximab Vedotin (SGN-35) for systemic anaplastic large cell lymphoma, 2010. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00866047"},{"key":"2025100303332068000_8.2.e001235.84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049"},{"key":"2025100303332068000_8.2.e001235.85","unstructured":"Seattle Genetics, Inc, Millennium Pharmaceuticals, Inc . ECHELON-2: A Comparison ofBrentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas 2018 [updated August 15]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01777152"},{"key":"2025100303332068000_8.2.e001235.86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"2025100303332068000_8.2.e001235.87","unstructured":"Millennium Pharmaceuticals, Inc, Seattle Genetics, Inc, Takeda . A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician\u2019s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) 2016 [updated May 31]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01578499"},{"key":"2025100303332068000_8.2.e001235.88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598763"},{"key":"2025100303332068000_8.2.e001235.89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2016.11.009","article-title":"Brentuximab vedotin for treatment of non-Hodgkin lymphomas: a systematic review","volume":"109","author":"Berger","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025100303332068000_8.2.e001235.90","unstructured":"Hoffman-La Roche, ClinicalTrials.gov Bethesda (MD): National Library of Medicine (US) . Identifier NCT02257567, a study of Polatuzumab Vedotin (DCDS4501A) in combination with rituximab or Obinutuzumab plus bendamustine in participants with relapsed or refractory follicular or diffuse large B-cell lymphoma."},{"key":"2025100303332068000_8.2.e001235.91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172"},{"key":"2025100303332068000_8.2.e001235.92","unstructured":"Genentech . POLIVY prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761121"},{"key":"2025100303332068000_8.2.e001235.93","unstructured":"Kyowa Kirin Pharmaceutical Development, Inc . Study of KW-0761 versus vorinostat in relapsed\/refractory CTCL 2017 [updated March]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01728805"},{"key":"2025100303332068000_8.2.e001235.94","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30379-6"},{"key":"2025100303332068000_8.2.e001235.95","unstructured":"Kyowa K . POTELIGEO prescribing information Tokyo, Japan. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761051"},{"key":"2025100303332068000_8.2.e001235.96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01389"},{"key":"2025100303332068000_8.2.e001235.97","unstructured":"Merck Sharp & Dohme Corp . Study of pembrolizumab (MK-3475) in participants with relapsed or refractory primary mediastinal large b-cell lymphoma or relapsed or refractory richter syndrome (MK-3475-170\/KEYNOTE-170) 2019 [updated June 29]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT02576990"},{"key":"2025100303332068000_8.2.e001235.98","unstructured":"Celgene . A study to determine the efficacy and safety of lenalidomide in patients with mantle cell nhl who have relapsed or progressed after treatment with bortezomib or are refractory to bortezomib. The \"EMERGE\" Trial 2016 [updated April 6]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00737529"},{"key":"2025100303332068000_8.2.e001235.99","doi-asserted-by":"crossref","first-page":"E575","DOI":"10.1002\/ajh.24854","article-title":"Long-Term analysis of phase II studies of single-agent lenalidomide in relapsed\/refractory mantle cell lymphoma","volume":"92","author":"Witzig","year":"2017","journal-title":"Am J Hematol"},{"key":"2025100303332068000_8.2.e001235.100","unstructured":"Celgene . Lenalidomide (REVLIMID) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021880"},{"key":"2025100303332068000_8.2.e001235.101","unstructured":"Celgene . Rituximab Plus Lenalidomide for Patients With Relapsed Refractory Indolent Non-Hodgkin\u2019s Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) 2018 [updated June 22]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01938001"},{"key":"2025100303332068000_8.2.e001235.102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00010"},{"key":"2025100303332068000_8.2.e001235.103","unstructured":"Celgene . Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed\/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma 2023 [updated April 8]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01996865"},{"key":"2025100303332068000_8.2.e001235.104","doi-asserted-by":"crossref","unstructured":"Andorsky DJ , Coleman M , Yacoub A , et al . MAGNIFY: phase IIIB interim analysis of induction R2 followed by maintenance in relapsed\/refractory indolent non-Hodgkin lymphoma. J Clin Oncol 2019;37. 7513.doi:10.1200\/JCO.2019.37.15_suppl.7513","DOI":"10.1200\/JCO.2019.37.15_suppl.7513"},{"key":"2025100303332068000_8.2.e001235.105","unstructured":"Celgene, The Lymphoma Academic Research Organisation . Combined rituximab and lenalidomide treatment for untreated patients with follicular lymphoma (relevance). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01476787"},{"key":"2025100303332068000_8.2.e001235.106","unstructured":"The Lymphoma Academic Research Organisation, Celgene . A phase 3 open label randomized study to compare the efficacy and safety of rituximab plus lenalidomide (CC-5013) versus rituximab plus chemotherapy followed by rituximab in subjects with previously untreated follicular lymphoma (relevance). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01650701"},{"key":"2025100303332068000_8.2.e001235.107","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805104"},{"key":"2025100303332068000_8.2.e001235.108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2818"},{"key":"2025100303332068000_8.2.e001235.109","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"2025100303332068000_8.2.e001235.110","unstructured":"Kite, A Gilead Company, Gilead Sciences . Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma 2020 [updated August]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT02348216"},{"key":"2025100303332068000_8.2.e001235.111","unstructured":"Kite Pharma, Incorporated . YESCARTA (axicabtagene ciloleucel): food and drug administration, 2017. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel"},{"key":"2025100303332068000_8.2.e001235.112","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2025100303332068000_8.2.e001235.113","unstructured":"Novartis Pharmaceuticals . KYMRIAH (tisagenlecleucel): food and drug administration, 2018. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel"},{"key":"2025100303332068000_8.2.e001235.114","unstructured":"Food and Drug Administration . TECARTUS (brexucabtagene autoleucel). Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel"},{"key":"2025100303332068000_8.2.e001235.115","unstructured":"Kite, A Gilead Company, Gilead Sciences . A phase 2 multicenter study evaluating subjects with relapsed\/refractory mantle cell lymphoma 2019 [updated July 24]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT02601313"},{"key":"2025100303332068000_8.2.e001235.116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"2025100303332068000_8.2.e001235.117","unstructured":"Morphosys AG . A study to evaluate the safety and efficacy of lenalidomide with MOR00208 in patients with R-R DLBCL (L-MIND). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02399085"},{"key":"2025100303332068000_8.2.e001235.118","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"2025100303332068000_8.2.e001235.119","unstructured":"Morphosys US Inc . MONJUVI prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761163"},{"key":"2025100303332068000_8.2.e001235.120","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2019.00295","article-title":"Refractory Epstein-Barr Virus (EBV)-related post-transplant lymphoproliferative disease: cure by combined brentuximab vedotin and Allogeneic EBV-speSpecific T-lyLymphocytes","volume":"6","author":"Mika","year":"2019","journal-title":"Front Med"},{"key":"2025100303332068000_8.2.e001235.121","unstructured":"Hoffmann-La Roche, German C. L. L. Study Group . Fludarabine and cyclophosphamide with or without rituximab in patients with previously untreated chronic B-cell lymphocytic leukemia 2007 [updated July]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00281918"},{"key":"2025100303332068000_8.2.e001235.122","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651125"},{"key":"2025100303332068000_8.2.e001235.123","unstructured":"Hoffmann-La Roche, Biogen, Genentech, Inc . FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients 2008 [updated July 23]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00090051"},{"key":"2025100303332068000_8.2.e001235.124","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"2025100303332068000_8.2.e001235.125","unstructured":"Pharmacyclics . IMBRUVICA prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=205552"},{"key":"2025100303332068000_8.2.e001235.126","unstructured":"National Cancer Institute . Ibrutinib and rituximab compared with fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic Leukemiaor small lymphocytic lymphoma. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02048813"},{"key":"2025100303332068000_8.2.e001235.127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"2025100303332068000_8.2.e001235.128","unstructured":"Hoffmann-La Roche, German C. L. L. Study Group, Genentech, Inc . CLL11: a study of obinutuzumab (ro5072759 ga101) with chlorambucil in patients with previously untreated chroniclymphocytic leukemia (Stage 1a) 2012 [updated July 1]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT01010061"},{"key":"2025100303332068000_8.2.e001235.129","unstructured":"Goede V , Fischer K , Dyer MJ , et al , eds. Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 STUDY. 23rd Congress of the European Hematology Association. Stockholm, Sweden, 2018."},{"key":"2025100303332068000_8.2.e001235.130","unstructured":"Novartis Pharmaceuticals . Ofatumumab + Chlorambucil vs chlorambucil monotherapy in previously untreated patients with chronic lymphocytic leukemia 2013 [updated March 20]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00748189"},{"key":"2025100303332068000_8.2.e001235.131","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60027-7"},{"key":"2025100303332068000_8.2.e001235.132","unstructured":"Glaxo Grp, Ltd . ARZERRA prescribing information Basel, Switzerland. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125326"},{"key":"2025100303332068000_8.2.e001235.133","unstructured":"GlaxoSmithKline, Genmab . Efficacy and safety of ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL) 2011 [updated September]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00802737"},{"key":"2025100303332068000_8.2.e001235.134","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(15)00143-6","article-title":"Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (prolong): an open-label, multicentre, randomised phase 3 study","volume":"16","author":"van Oers","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025100303332068000_8.2.e001235.135","unstructured":"Novartis Pharmaceuticals . Ofatumumab added to fludarabine-cyclophosphamide vs fludarabine-cyclophosphamide combination in relapsed subjects with chronic lymphocytic leukemia 2014 [updated December 17]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00824265"},{"key":"2025100303332068000_8.2.e001235.136","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/10428194.2016.1233536","article-title":"Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the complement 2 trial","volume":"58","author":"Robak","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2025100303332068000_8.2.e001235.137","unstructured":"GlaxoSmithKline . HuMax-CD20 in B-Cell chronic lymphocytic leukemia (B-CLL) patients failing fludarabine and alemtuzumab 2008 [updated May]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00349349"},{"key":"2025100303332068000_8.2.e001235.138","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3187"},{"key":"2025100303332068000_8.2.e001235.139","unstructured":"Genzyme, a Sanofi Company, Sanofi . Efficacy\/Safety of frontline alemtuzumab (Campath, MabCampath) vs chlorambucil in patients with progressive B-cell lymphocytic leukemia. Available: https:\/\/ClinicalTrials.gov\/show\/NCT00046683"},{"key":"2025100303332068000_8.2.e001235.140","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9098"},{"key":"2025100303332068000_8.2.e001235.141","unstructured":"Genzyme . Campath (alemtuzumab) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=103948"},{"key":"2025100303332068000_8.2.e001235.142","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1200\/JCO.1997.15.4.1567","article-title":"Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study group of CAMPATH-1H treatment in chronic lymphocytic leukemia","volume":"15","author":"Osterborg","year":"1997","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.143","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"2025100303332068000_8.2.e001235.144","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11551"},{"key":"2025100303332068000_8.2.e001235.145","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2025100303332068000_8.2.e001235.146","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","article-title":"A review of autologous stem cell transplantation in lymphoma","volume":"12","author":"Zahid","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"2025100303332068000_8.2.e001235.147","doi-asserted-by":"crossref","first-page":"FSO322","DOI":"10.4155\/fsoa-2018-0049","article-title":"Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma","volume":"4","author":"Galaznik","year":"2018","journal-title":"Future Sci OA"},{"key":"2025100303332068000_8.2.e001235.148","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000324"},{"key":"2025100303332068000_8.2.e001235.149","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761346"},{"key":"2025100303332068000_8.2.e001235.150","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025100303332068000_8.2.e001235.151","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-125039","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after programmed cell death 1 (PD-1) \/ programmed cell death ligand 1 (PD-L1) blockade for classical Hodgkin lymphoma: analysis of a large international cohort","volume":"134","author":"Merryman","year":"2019","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.152","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025100303332068000_8.2.e001235.153","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130195","article-title":"Comparison of CART19 and autologous stem-cell transplantation for refractory\/relapsed non-Hodgkin\u2019s lymphoma","volume":"5","author":"Li","year":"2019","journal-title":"JCI Insight"},{"key":"2025100303332068000_8.2.e001235.154","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.hoc.2019.03.005","article-title":"Allogeneic stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy for the treatment of non-Hodgkin lymphoma","volume":"33","author":"Hunter","year":"2019","journal-title":"Hematol Oncol Clin North Am"},{"key":"2025100303332068000_8.2.e001235.155","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"2025100303332068000_8.2.e001235.156","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"2025100303332068000_8.2.e001235.157","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-018-3368-8","article-title":"The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review","volume":"97","author":"Jin","year":"2018","journal-title":"Ann Hematol"},{"key":"2025100303332068000_8.2.e001235.158","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.252.252","article-title":"Anti-CD19 bite Blinatumomab induces high complete remission rate in adult patients with relapsed B-Precursor all: updated results of an ongoing phase II trial","volume":"118","author":"Topp","year":"2011","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.159","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-directed therapy","volume":"64","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"2025100303332068000_8.2.e001235.160","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.161","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100303332068000_8.2.e001235.162","unstructured":"Genentech . ACTEMRA prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125276"},{"key":"2025100303332068000_8.2.e001235.163","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"2025100303332068000_8.2.e001235.164","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"2025100303332068000_8.2.e001235.165","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"2025100303332068000_8.2.e001235.166","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100303332068000_8.2.e001235.167","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26333","article-title":"Adverse events to monoclonal antibodies used for cancer therapy: focus on hypersensitivity responses","volume":"2","author":"Baldo","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025100303332068000_8.2.e001235.168","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"2025100303332068000_8.2.e001235.169","unstructured":"National Cancer Institute Woyach J . Duvelisib and nivolumab in treating patients with Richter syndrome or transformed follicular lymphoma. Available: https:\/\/ClinicalTrials.gov\/show\/NCT03892044"},{"key":"2025100303332068000_8.2.e001235.170","unstructured":"H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp, Dohme Corp . Ibrutinib and PD-1 blockade in high risk lymphocytic leukemia 2021 [updated December]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT03514017"},{"key":"2025100303332068000_8.2.e001235.171","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e31815ef825"},{"key":"2025100303332068000_8.2.e001235.172","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0006"},{"key":"2025100303332068000_8.2.e001235.173","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-601"},{"key":"2025100303332068000_8.2.e001235.174","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006341717398"},{"key":"2025100303332068000_8.2.e001235.175","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111061","article-title":"Comparison of efficacy and toxicity of CD19-specific chimeric antigen receptor T-cells alone or in combination with ibrutinib for relapsed and\/or refractory CLL","volume":"132","author":"Gauthier","year":"2018","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.176","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/14653241003709686","article-title":"Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience","volume":"12","author":"Cruz","year":"2010","journal-title":"Cytotherapy"},{"key":"2025100303332068000_8.2.e001235.177","doi-asserted-by":"crossref","first-page":"iv100","DOI":"10.1093\/annonc\/mdx216","article-title":"Management of infusion reactions to systemic anticancer therapy: ESMO clinical practice guidelines","volume":"28","author":"Rosell\u00f3","year":"2017","journal-title":"Annals of Oncology"},{"key":"2025100303332068000_8.2.e001235.178","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.238.238","article-title":"Incidence of treatment-related, laboratory and clinical tumor lysis syndrome","volume":"120","author":"Cairo","year":"2012","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.179","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review","volume":"95","author":"Howard","year":"2016","journal-title":"Ann Hematol"},{"key":"2025100303332068000_8.2.e001235.180","first-page":"563","article-title":"Tumor lysis syndrome in patients with hematological malignancies","volume":"95","author":"Belay","year":"2017","journal-title":"Annals of Hematology"},{"key":"2025100303332068000_8.2.e001235.181","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"2025100303332068000_8.2.e001235.182","unstructured":"Butterfield LH , Kaufman HL , Johnson DH , et al . SITC\u2019s Guide to Managing Immunotherapy Toxicity. 1 ed. New York: Springer Publishing Company."},{"key":"2025100303332068000_8.2.e001235.183","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2025100303332068000_8.2.e001235.184","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0645-6"},{"key":"2025100303332068000_8.2.e001235.185","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100303332068000_8.2.e001235.186","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0013"},{"key":"2025100303332068000_8.2.e001235.187","doi-asserted-by":"publisher","DOI":"10.2741\/2000"},{"key":"2025100303332068000_8.2.e001235.188","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000327"},{"key":"2025100303332068000_8.2.e001235.189","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.019"},{"key":"2025100303332068000_8.2.e001235.190","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1182\/bloodadvances.2019000717","article-title":"Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy","volume":"3","author":"Hill","year":"2019","journal-title":"Blood Adv"},{"key":"2025100303332068000_8.2.e001235.191","first-page":"CE1","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"49(RR-10","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"2025100303332068000_8.2.e001235.192","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced Cancer\u2014A phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100303332068000_8.2.e001235.193","unstructured":"National Cancer Institute . Pembrolizumab in treating patients with hiv and relapsed, refractory, or disseminated malignant neoplasms 2020 [updated July 1]. Available: https:\/\/ClinicalTrials.gov\/show\/NCT02595866"},{"key":"2025100303332068000_8.2.e001235.194","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100303332068000_8.2.e001235.195","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100303332068000_8.2.e001235.196","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS"},{"key":"2025100303332068000_8.2.e001235.197","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CJI.0000000000000240","article-title":"Nivolumab treatment for cancers in the HIV-infected population","volume":"41","author":"Chang","year":"2018","journal-title":"J Immunother"},{"key":"2025100303332068000_8.2.e001235.198","doi-asserted-by":"crossref","first-page":"TPS44","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS44","article-title":"AIDS malignancy consortium (AMC) 095: a phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV-associated solid tumors (ST) with expansion cohorts in HIV-associated solid tumors and classical Hodgkin lymphoma (cHL)","volume":"36","author":"Rajdev","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"2025100303332068000_8.2.e001235.199","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00968-1"},{"key":"2025100303332068000_8.2.e001235.200","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1002\/cncr.32411","article-title":"Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma","volume":"125","author":"Abramson","year":"2019","journal-title":"Cancer"},{"key":"2025100303332068000_8.2.e001235.201","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26723"},{"key":"2025100303332068000_8.2.e001235.202","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4684"},{"key":"2025100303332068000_8.2.e001235.203","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i22.6716"},{"key":"2025100303332068000_8.2.e001235.204","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2025100303332068000_8.2.e001235.205","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"2025100303332068000_8.2.e001235.206","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-007-0397-0"},{"key":"2025100303332068000_8.2.e001235.207","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ehm.10.77","article-title":"Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab","volume":"4","author":"Vallejo","year":"2011","journal-title":"Expert Rev Hematol"},{"key":"2025100303332068000_8.2.e001235.208","doi-asserted-by":"crossref","unstructured":"Frisque RJ , White FA , Roos RP . The molecular biology of JC virus, causative agent of progressive multifocal leukoencephalopathy. In: Roos RP , ed. Molecular Neurovirology: pathogenesis of viral CNS infections. Totowa, NJ: Humana Press, 1992: 25\u2013158.","DOI":"10.1007\/978-1-4612-0407-7_2"},{"key":"2025100303332068000_8.2.e001235.209","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.5.1.49"},{"key":"2025100303332068000_8.2.e001235.210","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3675.3675","article-title":"Incidence of progressive multifocal leukoencephalopathy in non-Hodgkin lymphoma patients treated with rituximab","volume":"114","author":"Focosi","year":"2009","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.211","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.54.3.743","article-title":"AIDS- and non-AIDS-related PML association with distinct p53 polymorphism","volume":"54","author":"Power","year":"2000","journal-title":"Neurology"},{"key":"2025100303332068000_8.2.e001235.212","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.31"},{"key":"2025100303332068000_8.2.e001235.213","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program . Cancer STAT facts: non-Hodgkin lymphoma. Cancer Stat Facts: Non-Hodgkin lymphoma, 2017. https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html"},{"key":"2025100303332068000_8.2.e001235.214","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.1988.6.12.1838","article-title":"The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin\"s lymphoma","volume":"6","author":"Vose","year":"1988","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.215","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2001.n.002","article-title":"The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL)","volume":"1","author":"Bertini","year":"2001","journal-title":"Clin Lymphoma"},{"key":"2025100303332068000_8.2.e001235.216","unstructured":"Data on File . NIVO 254. Bristol-Myers Squibb Company, 2017."},{"key":"2025100303332068000_8.2.e001235.217","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"2025100303332068000_8.2.e001235.218","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.10009","article-title":"Fda analysis of enrollment of older adults in clinical trials for cancer drug registration: a 10-year experience by the U.S. food and drug administration","volume":"35","author":"Singh","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.219","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-119974"},{"key":"2025100303332068000_8.2.e001235.220","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"2025100303332068000_8.2.e001235.221","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.222","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0585-1"},{"key":"2025100303332068000_8.2.e001235.223","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40487-016-0038-7","article-title":"Patient reported outcomes (pros) as part of value-based care can shape therapy guidelines: impact on emerging targeted agents and immunotherapy protocols in resource-limited regions","volume":"5","author":"Mott","year":"2017","journal-title":"Oncol Ther"},{"key":"2025100303332068000_8.2.e001235.224","unstructured":"Community CS . The necessity of immunotherapy education for cancer patients Washington D.C. Available: https:\/\/www.cancersupportcommunity.org\/blog\/2017\/11\/necessity-immunotherapy-education-cancer-patients"},{"key":"2025100303332068000_8.2.e001235.225","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl494"},{"key":"2025100303332068000_8.2.e001235.226","doi-asserted-by":"publisher","DOI":"10.1177\/1758834010395342"},{"key":"2025100303332068000_8.2.e001235.227","unstructured":"National Cancer Institute . Patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE\u2122). Available: https:\/\/healthcaredelivery.cancer.gov\/pro-ctcae\/"},{"key":"2025100303332068000_8.2.e001235.228","unstructured":"European Organisation for Research and Treatment of Cancer . Quality of life group website. Available: https:\/\/qol.eortc.org\/"},{"key":"2025100303332068000_8.2.e001235.229","unstructured":"M. D. Anderson Cancer Center . The MD Anderson symptom inventory. Available: https:\/\/www.mdanderson.org\/research\/departments-labs-institutes\/departments-divisions\/symptom-research\/symptom-assessment-tools\/md-anderson-symptom-inventory.html"},{"key":"2025100303332068000_8.2.e001235.230","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7577","article-title":"Quality of life in cutaneous T-cell lymphoma subjects treated with anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat: results from the phase 3 MAVORIC trial","volume":"36","author":"Porcu","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"2025100303332068000_8.2.e001235.231","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1200\/JCO.2019.37.15_suppl.6594","article-title":"Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT)","volume":"37","author":"Sidana","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"2025100303332068000_8.2.e001235.232","doi-asserted-by":"publisher","DOI":"10.1172\/JCI94306"},{"key":"2025100303332068000_8.2.e001235.233","article-title":"High\u2010dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025100303332068000_8.2.e001235.234","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of car T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100303332068000_8.2.e001235.235","doi-asserted-by":"crossref","first-page":"166","DOI":"10.21037\/atm.2018.03.28","article-title":"Financial toxicity and implications for cancer care in the era of molecular and immune therapies","volume":"6","author":"Tran","year":"2018","journal-title":"Ann Transl Med"},{"key":"2025100303332068000_8.2.e001235.236","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100303332068000_8.2.e001235.237","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"2025100303332068000_8.2.e001235.238","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.011049"},{"key":"2025100303332068000_8.2.e001235.239","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29808"},{"key":"2025100303332068000_8.2.e001235.240","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1038\/bmt.2017.241","article-title":"Car-T cells: the narrow path between hope and bankruptcy?","volume":"52","author":"Chabannon","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2025100303332068000_8.2.e001235.241","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"}],"updated-by":[{"DOI":"10.1136\/jitc-2020-001235corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000}}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-001235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T10:33:50Z","timestamp":1759487630000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":241,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,12,24]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/jitc-2020-001235"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-001235","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}